Food Factors with Glucagon-Like Peptide-1 Releasing Activity Improve Glucose Tolerance

The metabolic sweetener shift

You do not need another sugar that just tastes good. You need ingredients that do something useful after they hit the gut. This paper points to two candidates: D-allulose and resistant maltodextrin. Both trigger glucagon-like peptide-1 (GLP-1), the same hormone that drives the newest generation of weight-loss drugs. But they work as food factors, not injectables.

Background: GLP-1 and food signals

GLP-1 comes from enteroendocrine L cells in the gut. After a meal, those cells release it into circulation. GLP-1 then stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety to the brain. That makes it a central target for diabetes and obesity management.

Most formulators know GLP-1 from pharmacology. But the gut releases it naturally in response to certain nutrients. The question is which food ingredients trigger that release reliably. The paper reviews that question.

What the study did

The paper appears in the International Journal of Molecular Sciences, volume 22, article 6623, DOI: 10.3390/ijms22126623. The authors looked at food-derived factors with GLP-1 releasing activity and tested whether those factors improve glucose tolerance.

They focused on non-metabolizable sugars and fermentable carbohydrates. D-allulose stood out because the body absorbs it but does not metabolize it. Resistant maltodextrin (RMD) stood out because it ferments in the colon. Both produce GLP-1 release, but through different mechanisms.

Experiments used rat and mouse models. The team measured plasma GLP-1, glucose tolerance, feeding behavior, and in some cases GIP, the other major incretin hormone.

Key findings

D-allulose promoted GLP-1 release in both rats and mice. Oral D-allulose increased GLP-1 secretion in mice, and that increase suppressed overeating and hyperglycemia. The effect was specific. D-allulose did not change GIP secretion. That specificity matters for product development. You can target GLP-1 without broadly altering the entire incretin system.

Resistant maltodextrin worked differently. Continuous feeding of RMD raised plasma GLP-1 in normal rats and in rats on a high-fat/high-sucrose diet. The rise in GLP-1 came with an increase in short-chain fatty acid production. That points to a fermentation-driven pathway. SCFAs, produced by gut bacteria, act as signals that stimulate L cells.

Ingredient	GLP-1 effect	GIP effect	Additional observation
D-allulose	Promotes GLP-1 release	No effect	Suppresses overeating and hyperglycemia in mice
Resistant maltodextrin (RMD)	Increases plasma GLP-1	Not reported in reviewed evidence	Raises short-chain fatty acid production

What it means for formulators and buyers

D-allulose gives you something rare: a sweetener with hormonal activity. It is non-metabolizable, so it contributes minimal calories, but it still triggers a gut hormone that supports glucose control and appetite regulation. That opens the door for beverages, bars, and confections positioned around metabolic health. You can formulate for sweetness and then let the ingredient carry part of the glucose-management story.

RMD gives you the fiber route. Because it works through fermentation, it may fit products already labeled as high-fiber or prebiotic. The SCFA connection adds a plausible mechanism for GLP-1 release. For buyers, that means you are not just buying a bulking agent. You are buying a signaling ingredient.

Both ingredients remain animal-model validated. The paper does not provide human clinical data. Formulators should still treat this as a strong mechanistic foundation, not a finished claim. Regulatory language will need to match the evidence.

FAQ

Does D-allulose behave like a GLP-1 drug?

No. D-allulose stimulates the body's natural GLP-1 release. It is not a GLP-1 receptor agonist. The effect is milder and nutrient-dependent, but it offers a food-based route to activation.

Can resistant maltodextrin replace D-allulose?

Not necessarily. RMD increases GLP-1 through SCFA production, while D-allulose acts directly on L cells. The paper does not test a combination, but the two mechanisms could complement each other.

Are these effects confirmed in humans?

The evidence in this paper comes from rat and mouse models. Human translation is plausible but not proven here. Buyers should look for human trials before making strong claims.

GLP-1 is not just a drug target anymore. It is a food-relevant signal. D-allulose and resistant maltodextrin offer two distinct ways to activate it, and both improve glucose tolerance in animal studies. That is the kind of functional edge formulators should watch.